A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Phase 3
510
about 4.6 years
18+
6 sites in CA, MI, TN +2
What this study is about
Researchers are testing if a treatment called ifinatamab deruxtecan, given with chemotherapy, can help people who have advanced esophageal squamous cell carcinoma. The trial will compare this new treatment to standard chemotherapy options.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Docetaxel
- 2.Take Ifinatamab deruxtecan
- 3.Take Irinotecan hydrochloride (HCl)
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
docetaxel, Antineoplastic Agent [TC] (Topoisomerase Inhibitors), paclitaxel (Taxane chemotherapy; stabilizes microtubules)
infusion, injection, intravenous
Primary: Overall Survival (OS)
Secondary: Change from baseline in European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire Score (EORTC QLQ-C30), Change from baseline in European Organisation for Research and Treatment of Cancer Esophageal Cancer Module Score (EORTC OES18), Disease Control Rate (DCR), Duration of Response (DoR), Incidence of Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and Adverse Events of Special Interest (AESIs), Objective Response Rate (ORR), Pharmacokinetic Parameter Time to Maximum Concentration (Tmax) for I-DXd, Pharmacokinetic Parameter Time to Maximum Concentration (Tmax) for MAAA-1181a
Oncology